StockNews.com began coverage on shares of NovaBay Pharmaceuticals (NYSE:NBY – Free Report) in a report published on Saturday morning. The firm issued a hold rating on the stock.
NovaBay Pharmaceuticals Stock Up 8.5 %
Shares of NBY stock opened at $0.53 on Friday. NovaBay Pharmaceuticals has a fifty-two week low of $0.36 and a fifty-two week high of $17.74. The stock has a market cap of $573,351.80, a P/E ratio of 0.00 and a beta of 0.73. The business has a fifty day simple moving average of $0.89 and a 200-day simple moving average of $2.55.
NovaBay Pharmaceuticals (NYSE:NBY – Get Free Report) last announced its quarterly earnings results on Tuesday, August 13th. The company reported ($1.37) earnings per share for the quarter. NovaBay Pharmaceuticals had a negative net margin of 91.86% and a negative return on equity of 744.33%. The firm had revenue of $2.40 million during the quarter. On average, sell-side analysts anticipate that NovaBay Pharmaceuticals will post -0.17 earnings per share for the current year.
Institutional Trading of NovaBay Pharmaceuticals
About NovaBay Pharmaceuticals
NovaBay Pharmaceuticals, Inc, a biopharmaceutical company, develops and sells eyecare, skincare, and wound care products in the United States and internationally. It offers Avenova Spray, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; and wound care products, which are used for cleansing and irrigation as part of surgical procedures, as well as treating certain wounds, burns, ulcers, and other injuries under the NeutroPhase and PhaseOne brands.
Featured Articles
- Five stocks we like better than NovaBay Pharmaceuticals
- 3 Tickers Leading a Meme Stock Revival
- Galmed Pharmaceuticals Surges 400%: What’s Behind the Explosion?
- What does consumer price index measure?
- Gold Hits New All-Time Highs: 3 Stocks to Ride the Surge
- Investing in Commodities: What Are They? How to Invest in Them
- Intel: Why It’s Time to Reconsider This Beaten-Down Chipmaker
Receive News & Ratings for NovaBay Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NovaBay Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.